High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: Significance for cardiovascular risk - The IDEAL and EPIC-Norfolk studies

被引:311
作者
van der Steeg, Wim A. [1 ]
Holme, Ingar [2 ]
Boekholdt, S. Matthijs [1 ]
Larsen, Mogens Lytken [3 ]
Lindahl, Christina [4 ]
Stroes, Erik S. G. [1 ]
Tikkanen, Matti J. [5 ]
Wareham, Nicholas J. [6 ]
Faergeman, Ole [3 ]
Olsson, Anders G. [7 ]
Pedersen, Terje R. [2 ]
Khaw, Kay-Tee [8 ]
Kastelein, John J. P. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Ullevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway
[3] Dept Med Cardiol A, Aarhus, Denmark
[4] Pfizer Sweden, Taby, Sweden
[5] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland
[6] MRC, Epidemiol Unit, Cambridge, England
[7] Linkoping Univ Hosp, Dept Internal Med, S-58185 Linkoping, Sweden
[8] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
D O I
10.1016/j.jacc.2007.09.060
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and apolipoprotein A-I (apoA-I) with the occurrence of coronary artery disease (CAD), with a focus on the effect of very high values of these parameters. Background High plasma levels of HDL-C and apoA-I are inversely related to the risk of CAD. However, recent data suggest that this relationship does not hold true for very high HDL-C levels, particularly when a preponderance of large HDL particles is observed. Methods We conducted a post-hoc analysis of 2 prospective studies: the IDEAL (incremental Decrease in End Points through Aggressive Lipid Lowering; n = 8,888) trial comparing the efficacy of high-dose to usual-dose statin treatment for the secondary prevention of cardiovascular events, and the EPIC (European Prospective Investigation into Cancer and Nutrition)-Norfolk case-control study, including apparently healthy individuals who did (cases, n = 858) or did not (control patients, n = 1,491) develop CAD during follow-up. In IDEAL, only HDL-C and apoA-I were available; in EPIC-Norfolk, nuclear magnetic resonance spectroscopy-determined HDL particle sizes were also available. Results In the IDEAL study, higher HDL-C proved a significant major cardiac event risk factor following adjustment for age, gender, smoking, apoA-I, and apoB. A similar association was observed for HDL particle size in EPIC-Norfolk. Increased risk estimates were particularly present in the high ends of the distributions. In contrast, apoA-I remained negatively associated across the major part of its distribution in both studies. Conclusions When apoA-I and apoB are kept constant, HDL-C and HDL particle size may confer risk at very high values. This does not hold true for very high levels of apoA-I at fixed levels of HDL-C and apoB. These findings may have important consequences for assessment and treatment of CAD risk.
引用
收藏
页码:634 / 642
页数:9
相关论文
共 26 条
[1]  
ALBERS JJ, 1992, CLIN CHEM, V38, P658
[2]   The rationale for using apoA-I as a clinical marker of cardiovascular risk [J].
Barter, PJ ;
Rye, KA .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) :447-454
[3]   High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase [J].
Berard, AM ;
Foger, B ;
Remaley, A ;
Shamburek, R ;
Vaisman, BL ;
Talley, G ;
Paigen, B ;
Hoyt, RF ;
Marcovina, S ;
Brewer, HB ;
SantamarinaFojo, S .
NATURE MEDICINE, 1997, 3 (07) :744-749
[4]   Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds - A meta-analysis of randomized controlled trials [J].
Birjmohun, RS ;
Hutten, BA ;
Kastelein, JJP ;
Stroes, ESG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (02) :185-197
[5]   INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY [J].
CASTELLI, WP ;
GARRISON, RJ ;
WILSON, PWF ;
ABBOTT, RD ;
KALOUSDIAN, S ;
KANNEL, WB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20) :2835-2838
[6]   Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease [J].
Chapman, M. John .
PHARMACOLOGY & THERAPEUTICS, 2006, 111 (03) :893-908
[7]  
CHEUNG MC, 1991, J LIPID RES, V32, P383
[8]  
Day N, 1999, BRIT J CANCER, V80, P95
[9]   Emerging strategies for increasing high-density lipoprotein [J].
Forrester, James S. ;
Shah, Prediman K. .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (11) :1542-1549
[10]   HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].
GORDON, DJ ;
PROBSTFIELD, JL ;
GARRISON, RJ ;
NEATON, JD ;
CASTELLI, WP ;
KNOKE, JD ;
JACOBS, DR ;
BANGDIWALA, S ;
TYROLER, HA .
CIRCULATION, 1989, 79 (01) :8-15